Stifel analyst Stephen Willey resumed coverage of Disc Medicine (IRON) with a Buy rating and $125 price target The firm believes the company’s clinical-stage portfolio of assets targeting heme biosynthesis and iron bioavailability will prove clinically and commercially relevant across a broad spectrum of hematological disorders, the analyst tells investors. The firm believes the CNPV-accelerated commercialization of bitopertin in erythropoietic and X-linked protoporphyria and favorable confirmatory Phase 3 APOLLO trial prospects “create a clear path to longer-term profitability,” the analyst added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine’s APOLLO Study: A Potential Game-Changer for EPP and XLP Treatment
- Disc Medicine’s New Study on DISC-3405: A Potential Breakthrough for Sickle Cell Disease
- Disc Medicine’s Promising Phase 2 Study on DISC-3405 for Polycythemia Vera
- Disc Medicine’s Promising Anemia Treatment Study: Key Insights for Investors
- Disc Medicine’s Promising EPP Treatment Study: Key Updates and Market Impact